CMAB Biopharma

CMAB Biopharma is a China-based full-service contract development and manufacturing organization (CDMO) dedicated to providing process development and manufacturing services for biologic products. With a focus on delivering fully integrated CDMO services for biologics, the company offers bespoke development manufacturing services of antibodies and biologics for clients in China and globally. Located in Suzhou’s BioBAY Park, CMAB’s manufacturing facility follows global GMP standards and is supported by a team with strong expertise in the biologics CDMO industry. The company has quickly built up a team with a solid experience in the biopharmaceutical industry, currently consisting of over 160 employees, with plans to expand to more than 200 staff at the end of 2019. In terms of funding, CMAB completed its series A financing of US$38 million in January 2018, and a series B financing round of US$34 million in April 2018. The series A financing was led by C-Bridge Capital and BioBAY, with I-Bridge Capital and Qianhai FoF fund joining the consortium. The series B financing was secured with lead participation by CD Capital, with joint participation by C-Bridge Capital, Cormorant Capital, Qianhai FoF Fund, and Tigermed. Overall, CMAB Biopharma showcases a strong focus on providing comprehensive CDMO services for biologics, supported by a solid financial backing and a well-established team with extensive industry experience. For more information, visit their website at www.cmabbio.com or contact them directly at [email protected].